These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 37246638)

  • 1. MCM10: An effective treatment target and a prognostic biomarker in patients with uterine corpus endometrial carcinoma.
    Chen J; Wu S; Wang J; Han C; Zhao L; He K; Jia Y; Cui M
    J Cell Mol Med; 2023 Jun; 27(12):1708-1724. PubMed ID: 37246638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KDM4B, a potential prognostic biomarker revealed by large-scale public databases and clinical samples in uterine corpus endometrial carcinoma.
    Zhang M; Liu Y; Hou S; Wang Y; Wang C; Yin Y; Chen X
    Mol Omics; 2022 Jul; 18(6):506-519. PubMed ID: 35485290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction of prediction model for prognosis of uterine corpus endometrial carcinoma based on pyroptosis gene.
    Zhang C; Bai J; Yang Y; Wang X; Liu W; Hou S; Ai Z; Xia Q; Shao L
    Clin Transl Oncol; 2023 May; 25(5):1413-1424. PubMed ID: 36520385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FAT2 mutation is associated with better prognosis and responsiveness to immunotherapy in uterine corpus endometrial carcinoma.
    Wang Z; Xing L; Huang Y; Han P
    Cancer Med; 2023 Feb; 12(3):3797-3811. PubMed ID: 36812126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction of N-7 methylguanine-related mRNA prognostic model in uterine corpus endometrial carcinoma based on multi-omics data and immune-related analysis.
    Zhao J; Zou J; Jiao W; Lin L; Wang J; Lin Z
    Sci Rep; 2022 Nov; 12(1):18813. PubMed ID: 36335189
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Zhao Q; Chen G; Yang X; Wang T; Yuan S; Meng Q
    Comb Chem High Throughput Screen; 2023; 26(2):330-338. PubMed ID: 35379118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LINC01589 serves as a potential tumor-suppressor and immune-related biomarker in endometrial cancer: A review.
    Chen R; An J; Wang Y; Yang L; Lin Q; Wang Y
    Medicine (Baltimore); 2023 Apr; 102(15):e33536. PubMed ID: 37058060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KNL1 is a prognostic and diagnostic biomarker related to immune infiltration in patients with uterine corpus endometrial carcinoma.
    He K; Li J; Huang X; Zhao W; Wang K; Wang T; Chen J; Wang Z; Yi J; Zhao S; Zhao L
    Front Oncol; 2023; 13():1090779. PubMed ID: 36776306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. m
    Fang F; Wang P; Huang H; Ye M; Liu X; Li Q
    BMC Cancer; 2022 Dec; 22(1):1364. PubMed ID: 36581816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Five m6A-Related lncRNA Genes as Prognostic Markers for Endometrial Cancer Based on TCGA Database.
    Shan L; Lu Y; Xiang CC; Zhu X; Zuo ED; Cheng X
    J Immunol Res; 2022; 2022():2547029. PubMed ID: 35571565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs.
    Zhang X; Ye Z; Xiao G; He T
    Comput Biol Med; 2023 Jun; 159():106905. PubMed ID: 37060773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of PSAT1 inhibits cell proliferation and migration in uterine corpus endometrial carcinoma.
    Wang M; Yue S; Yang Z
    Sci Rep; 2023 Mar; 13(1):4081. PubMed ID: 36906716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Five-microRNA Signature as Risk Stratification System in Uterine Corpus Endometrial Carcinoma.
    Chen Z; Huang X; Lv Y; Fang Y; Pan L; Gan Z; Huang Z; Wei W
    Comb Chem High Throughput Screen; 2021; 24(2):187-194. PubMed ID: 32748742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MCM10 as a novel prognostic biomarker and its relevance to immune infiltration in gliomas.
    Tian QS; Zhang Q; Huang W
    Technol Health Care; 2023; 31(4):1301-1317. PubMed ID: 36872806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of methylation-driven genes prognosis signature and immune microenvironment in uterus corpus endometrial cancer.
    Liu J; Ji C; Wang Y; Zhang C; Zhu H
    Cancer Cell Int; 2021 Jul; 21(1):365. PubMed ID: 34246261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and validation of oxeiptosis-associated lncRNAs and prognosis-related signature genes to predict the immune status in uterine corpus endometrial carcinoma.
    Niu L; Wu Z
    Aging (Albany NY); 2023 May; 15(10):4236-4252. PubMed ID: 37211398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ferroptosis-Related lncRNA for the Establishment of Novel Prognostic Signature and Therapeutic Response Prediction to Endometrial Carcinoma.
    Zhou XY; Dai HY; Zhang H; Zhu JL; Hu H
    Biomed Res Int; 2022; 2022():2056913. PubMed ID: 35937391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycosyltransferase-related prognostic and diagnostic biomarkers of uterine corpus endometrial carcinoma.
    Wu J; Zhou X; Ren J; Zhang Z; Ju H; Diao X; Jiang S; Zhang J
    Comput Biol Med; 2023 Sep; 163():107164. PubMed ID: 37329616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CXC chemokines: Potential biomarker and immunotherapeutic target for uterine corpus endometrial carcinoma.
    Wang G; Fu J; Liu M; Zheng Q
    PLoS One; 2024; 19(1):e0277872. PubMed ID: 38232115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of an endoplasmic reticulum stress-related gene signature to predict prognosis and potential drugs of uterine corpus endometrial cancer.
    Zhou P; Wu C; Ma C; Luo T; Yuan J; Zhou P; Wei Z
    Math Biosci Eng; 2023 Jan; 20(2):4018-4039. PubMed ID: 36899615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.